Richard Socher's new $650 million startup wants to build an AI that can research and improve itself indefinitely — and he insists it will actually ship products.

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...

The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...

Anthropic's research suggests AI is increasingly used to develop and improve new AI systems, with Claude now writing over 80% ...

The maker of Claude wants the world to keep one option open. The timing is the tell.

Anthropic has warned that recursive-self-improving AI could be on the horizon, but the truth is the company is more ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive early clinical data from its AI driven drug discovery programs. The company highlighted progress in oncology and rare disease candidates in ...

Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.

In recent days, Recursion Pharmaceuticals reported positive early clinical data and advances in its AI-driven drug discovery pipeline, alongside a narrower-than-expected first-quarter EPS loss and ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion Pharmaceuticals announced positive Phase 1b/2 results from its ongoing TUPELO trial ...

Analysts and investors have been awaiting more proof that Recursion Pharma’s extensive and homegrown datasets can offer drug discovery platforms a speed-to-clinic edge. A $50 million investment the ...

As AI companies explore systems that can help develop more advanced AI, policymakers are beginning to debate whether new ...